The Department of Science and Technology (DOST) said today that the results of clinical trials for Lagundi to treat symptoms of mild COVID-19 cases may be released after two months.
DOST Secretary Fortunato dela Peña said the Food and Drug Administration (FDA) has approved the clinical trials for Lagundi as an adjunctive therapy for COVID-19.
READ MORE: Clinical trials for lagundi OK’d by FDA
However, he said the results will take some time.
“Okay na pong umpisahan ang trials pero it will take some months pa rin para matapos ‘yon. Siguro po baka mga dalawang buwan pa ‘yan (It is okay to start the trials but it will still take a few months to finish it. Maybe it will take for two months),” Dela Peña told DZMM Teleradyo.
Dela Peña said the clinical trials will be held at the Quezon Institute Quarantine Center, Philippine National Police-National Capital Region (PNP-NCR) Community Quarantine Center, and Sta. Ana Hospital.
The DoST Secretary said ''Tawa-Tawa,'' a herbal supplement for dengue patients, is now also on trial as a health supplement for COVID-19 cases.
“‘Yun namang Tawa-tawa ay sa dengue, ngayon sinusubukan din natin bilang health supplement din for COVID case. ‘Yan naman po ay may approval na siya hindi bilang gamot pa pero bilang health supplement, FDA approved din po (Tawa-Tawa is a herbal supplement for dengue, now we are also trying it as a health supplement for COVID cases. It has an approval not as a medicine but as a health supplement, FDA approved as well),” he said.
Dela Peña added that they are still awaiting 60 moderate and severe patients to undergo clinical trial for the use of Virgin Coconut Oil against COVID-19.
READ MORE: Lauric acid, derivatives, show efficacy vs COVID-19 virus